The DESTINY-Breast04 trial demonstrated, for the first time, that patients with HER-2 low-expressing breast cancers, including TNBC subtypes, could benefit from treatment with DS-8201a, which significantly improved HER-2 expression compared with chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.